Lucknow Father Pleads for Russian Cancer Vaccine Trial to Save Son's Life

In October 2025, Manu Srivastava, a father from Lucknow, India, made a heartfelt plea to the Russian government to include his 21-year-old son Ansh in the trials of a cancer vaccine developed in Russia. Ansh is currently battling stage 4 cancer, and the vaccine, which has shown promising results in preclinical trials, is not yet available in India.

Manu explained that his son's doctors in India have not been fully responsive, and he is worried about the uncertainty of Ansh's condition. When Manu learned about the Russian cancer vaccine, he immediately wrote to the governments of India and Russia, requesting that his son be included in the trials.

The Russian government has acknowledged Manu's request and is currently considering it. Meanwhile, the Indian government has informed Manu that the Russian-made vaccine is only being implemented in Russia, and no other country has yet received approval to conduct trials.

Despite the challenges, Manu remains hopeful that his son will be given a chance to access the experimental treatment. The Russian vaccine has successfully completed preclinical trials, demonstrating both safety and high efficacy in reducing tumor size and slowing tumor progression by 60% to 80%, according to the head of the Federal Medical and Biological Agency.